New antagonists of the interaction between the CCR1 Chemokine receptor and its ligands, including MIP-1α (CCL3), represented by formula (I) are disclosed, as well as pharmaceutical compositions comprising them and their use in therapy for the treatment of pathological conditions or diseases susceptible of being improved by antagonism of the CCR1 receptor.
本发明揭示了与其
配体(包括MI
P-1α(CCL3))的CCR1
趋化因子受体之间相互作用的新
拮抗剂,其表示为公式(I)。此外,还揭示了包含它们的制药组合物以及它们在治疗病理情况或疾病中的使用,这些病理情况或疾病可以通过抗CCR1受体的作用得到改善。